Vidasym

Chronic kidney disease (CKD) affects an estimated 350 million people worldwide. CKD is a progressive disease with large unmet medical needs, and growing in prevalence due to the epidemic of type 2 diabetes.

Vidasym has discovered a series of novel vitamin D receptor modulators (VDRMs), and phosphate binders that are highly differentiated from on-market products. The initial focus is to advance chronic kidney disease program into clinical development for chronic kidney disease indications.

Vidasym has also identified several VDR drug candidates for additional pharmaceutical markets, such as cancer-related thrombosis, osteoporosis and psoriasis.